Latest Breaking News On - Retinal eye research - Page 1 : comparemela.com

Oxurion NV Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for retinal vascular disorders, announces the publication of a review article describing the cutting-edge science and rationale for the design and development of THR-687. The article entitled:

United statesRegion flamandeWouter piepersSylvie berrebi frazer hallChristopher brinzeyCitigate dewe rogersonProgress in retinal eye researchBicycle therapeuticsCorporate communicationsRetinal eye researchEuronext brusselsVan hoveRetinal eyeAlan stittChief scientific officerஒன்றுபட்டது மாநிலங்களில்